Soya has been part of Asian diets for centuries, providing protein, fibre, and essential nutrients. Yet in the West, it has long been controversial. At the heart of the debate are isoflavones – plant compounds found in soy that act as phytoestrogens, meaning they can weakly bind to human oestrogen receptors.

Some people believe soy could feminise men, worsen hormone-related cancers, or interfere with oestrogen clearance. Others promote it as a safe, plant-based food with benefits for heart health and menopause. So, what does the science actually say?

Where the Soy Controversy Came From

The fear surrounding soy largely began with:

• Animal studies: Early rodent experiments showed reproductive changes when animals were fed high doses of isolated isoflavones. Since phytoestrogens can bind to oestrogen receptors, scientists worried they could mimic human oestrogen.

• Case reports: Rare human cases added fuel to the fire. In one widely cited example, a man developed breast enlargement after consuming several litres of soy milk daily – more than nine times the typical Asian intake.

• Media amplification: Headlines in the 2000s declared soy “the most dangerous food for men,” sparking fears of lowered testosterone, infertility, and cancer.

These early signals were never representative of normal soy consumption, but they shaped public perception for years.

What’s in Soy That Sparked Concern?

The compounds in soy that raised concern are isoflavones, a type of phytoestrogen (plant-derived molecule similar in structure to human oestrogen).

• Weak action: Isoflavones are 100–1000 times weaker than the body’s own oestrogen, but their similarity caused alarm.

• Selective binding: They bind more strongly to ERβ (beta) receptors than ERα (alpha). ERβ is linked to protective effects, while ERα overstimulation can be risky.

• Main compounds: Genistein, daidzein, and glycitein are the key isoflavones in soy.

• Gut metabolism: Isoflavone activity depends on gut bacteria, with some people producing a compound called equol, which may boost benefits.

Because they can bind to oestrogen receptors, isoflavones were suspected of lowering testosterone, disrupting fertility, or fuelling cancers. But large human studies have shown these fears to be unfounded.

Effects in Men: Hormones, Sperm Quality, and Fertility

• Testosterone & Oestradiol: Large meta-analyses consistently show no significant effect of soy or isoflavones on total or free testosterone, estradiol, or other reproductive hormones in men, regardless of dose or duration.

• Sperm Quality & Fertility: Most clinical studies report no adverse effects on sperm concentration, motility, morphology, or semen quality. One observational study in subfertile men found an association between higher soy intake and lower sperm concentration, but this did not affect other semen parameters and may not apply to the general population.

• Endocrine Disruption: Human data do not support classifying isoflavones as endocrine disruptors in men.

Takeaway for men: Soy does not lower testosterone, damage sperm quality, or impair fertility.

Effects in Women: Hormones, Fertility, and Cancer

• Oestradiol & Ovarian Reserve: Within typical dietary ranges, soy and isoflavone intake do not significantly affect estradiol levels, ovarian reserve (as measured by antral follicle count, AMH, or FSH), or fertility outcomes.

• Cancer Risk: Data suggest soy does not increase breast or endometrial cancer risk; in fact, some evidence points to a protective effect, particularly with early-life consumption.

• Postmenopausal Women: Soy isoflavones do not produce estrogenic effects on endometrial thickness, vaginal maturation, FSH, or estradiol in postmenopausal women.

Takeaway for women: Soy does not impair fertility or increase cancer risk, and it may provide protective benefits.

Menopause: Hot Flushes and Bone Health

Soy isoflavones have been studied as a natural alternative to hormone therapy.

• They can modestly reduce hot flushes, though effects may take several weeks.

• Some evidence suggests benefits for spinal bone density.

• Isoflavones are safe and generally well tolerated.

Takeaway: Soy can gently ease menopause symptoms and support bone health.

Oestrogen Clearance and Hormonal Balance

Soy does not increase oestrogen levels or block clearance. Trials show no impact on estradiol or uterine lining thickness. In fact, soy may slightly lengthen menstrual cycles, reducing lifetime oestrogen exposure.

How Soy Isoflavones Interact with Oestrogen Receptors

• ERα (alpha) – found in breast and uterine tissue; overstimulation can increase cancer risk.

• ERβ (beta) – found in bone, brain, prostate, and cardiovascular tissue; activation is linked to protective effects.

(Kim, 2021)

Soy isoflavones bind more strongly to ERβ, acting like natural selective oestrogen receptor modulators (SERMs). They can block stronger oestrogens in some tissues while supporting protective effects in others.

This explains why soy can relieve menopause symptoms and support bone health without fuelling cancers.

Cancer: Risk or Protection?

• Breast cancer: Soy intake is linked with lower risk, especially with early-life consumption. Breast cancer survivors who eat more soy also have lower recurrence and better survival.

• Prostate cancer: Men with higher soy intake have a lower risk.

• General safety: Reviews conclude soy is safe and may be protective.

Quick Comparison: Myths vs Evidence on Soya

Organic vs Non-Organic Soy

Most soy grown worldwide is GM and used in animal feed or processed oils, not in traditional soy foods. For human diets, both organic and conventional soy are beneficial, but differences exist.

Nutritional Differences

• Nutrient Density: Organic soy often contains higher levels of iron, magnesium, and vitamin C.

• Pesticide Residues: Organic soy avoids synthetic pesticides, lowering chemical exposure.

• Phytochemicals: Isoflavone and antioxidant levels may be higher in organic soy, linked to healthier soils.

Health Implications

• Chronic Disease Prevention: Soy intake is associated with reduced cardiovascular and cancer risk. Organic soy may enhance these effects thanks to higher nutrient density and fewer chemical residues.

• Hormonal Effects: Isoflavones act as phytoestrogens, improving menopausal symptoms and bone health, without adverse hormonal disruption.

Balanced Perspective

Organic soy provides the most nutritional and environmental benefits, but conventional soy foods still offer significant health advantages. Whole soy foods (tofu, tempeh, edamame, miso, soy milk) are preferable to isolates or oils.

Takeaway: Choose organic whole soy when possible, but any soy in whole-food form is a healthy choice.

Dietary Recommendations

• Safe intake: 1–2 servings daily (e.g. 1 cup soy milk, ½ cup tofu, or a handful of edamame).

• Upper safe levels: 3–4 servings daily have been shown safe.

• Best forms: Whole foods are best; supplements may help menopause symptoms.

The Bottom Line

The soy scare came from animal studies and extreme case reports, not typical human diets. Today’s evidence shows:

• Soy does not feminise men or lower testosterone.

• Soy does not impair fertility in men or women.

• Soy may ease menopause symptoms and support bone health.

• Soy does not overload oestrogen clearance.

• Soy preferentially binds ERβ, offering protective effects.

• Soy is linked with lower risk of breast and prostate cancers.

• Organic soy provides added benefits, but all whole soy foods are safe and nutritious.

Soya is safe, nutrient-rich, and backed by science – a powerful example of how myths can be overturned by good evidence.

References:

• Applegate, C.C. et al. (2018) ‘Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis’, Nutrients, 10(1), p. 40. Available at: https://doi.org/10.3390/nu10010040.

• Chen, M. et al. (2014) ‘Association between Soy Isoflavone Intake and Breast Cancer Risk for Pre- and Post-Menopausal Women: A Meta-Analysis of Epidemiological Studies’, PLOS ONE, 9(2), p. e89288. Available at: https://doi.org/10.1371/journal.pone.0089288.

• Messia, M. et al. (2021) ‘Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data’, Critical Reviews in Food Science and Nutrition, 62(21), pp. 5824-5885 Available at: https://www.tandfonline.com/doi/full/10.1080/10408398.2021.1895054.

• Gómez-Zorita, S. et al. (2020) ‘Scientific Evidence Supporting the Beneficial Effects of Isoflavones on Human Health’, Nutrients, 12(12), p. 3853. Available at: https://doi.org/10.3390/nu12123853.

• Kim, I.-S. (2021) ‘Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans’, Antioxidants, 10(7), p. 1064. Available at: https://doi.org/10.3390/antiox10071064.

• Kim, I.-S., Kim, C.-H. and Yang, W.-S. (2021) ‘Physiologically Active Molecules and Functional Properties of Soybeans in Human Health—A Current Perspective’, International Journal of Molecular Sciences, 22(8), p. 4054. Available at: https://doi.org/10.3390/ijms22084054.

• Krebs, E.E. et al. (2004) ‘Phytoestrogens for Treatment of Menopausal Symptoms: A Systematic Review’, Obstetrics & Gynecology, 104(4), p. 824. Available at: https://doi.org/10.1097/01.AOG.0000140688.71638.d3.

• Kurzer, M.S. (2002) ‘Hormonal Effects of Soy in Premenopausal Women and Men’, The Journal of Nutrition, 132(3), pp. 570S–573S. Available at: https://doi.org/10.1093/jn/132.3.570S.

• Lethaby, A.E. et al. (2007) ‘Phytoestrogens for vasomotor menopausal symptoms’, The Cochrane Database of Systematic Reviews, (4), p. CD001395. Available at: https://doi.org/10.1002/14651858.CD001395.pub3.

• Li, L. et al. (2015) ‘Quantitative efficacy of soy isoflavones on menopausal hot flashes’, British Journal of Clinical Pharmacology, 79(4), pp. 593–604. Available at: https://doi.org/10.1111/bcp.12533.

• Liu, J. et al. (2016) ‘Oral isoflavone supplementation on endometrial thickness: a meta-analysis of randomized placebo-controlled trials’, Oncotarget, 7(14), pp. 17369–17379. Available at: https://doi.org/10.18632/oncotarget.7959.

• Martinez, J. and Lewi, J.E. (2008) ‘An unusual case of gynecomastia associated with soy product consumption’, Endocrine Practice, 14(4), pp. 415–418. Available at: https://doi.org/10.4158/EP.14.4.415.

• Messina, M. (2016) ‘Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature’, Nutrients, 8(12), p. 754. Available at: https://doi.org/10.3390/nu8120754.

• Messina, M. et al. (2022) ‘The health effects of soy: A reference guide for health professionals’, Frontiers in Nutrition, 9. Available at: https://doi.org/10.3389/fnut.2022.970364.

• Nogueira-de-Almeida, C.A. et al. (2020) ‘Impact of soy consumption on human health: integrative review’, Brazilian Journal of Food Technology, 23, p. e2019129. Available at: https://doi.org/10.1590/1981-6723.12919.

• Rahman, A. et al. (2024) ‘A Comprehensive Analysis of Organic Food: Evaluating Nutritional Value and Impact on Human Health’, Foods, 13(2), p. 208. Available at: https://doi.org/10.3390/foods13020208.

• Reed, K.E. et al. (2021) ‘Neither soy nor isoflavone intake affects male reproductive hormones: An expanded and updated meta-analysis of clinical studies’, Reproductive Toxicology, 100, pp. 60–67. Available at: https://doi.org/10.1016/j.reprotox.2020.12.019.

• Trock, B.J., Hilakivi-Clarke, L. and Clarke, R. (2006) ‘Meta-Analysis of Soy Intake and Breast Cancer Risk’, JNCI: Journal of the National Cancer Institute, 98(7), pp. 459–471. Available at: https://doi.org/10.1093/jnci/djj102.

• Viscardi, G. et al. (2024) ‘Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials’, Advances in Nutrition, 16(1), p. 100327. Available at: https://doi.org/10.1016/j.advnut.2024.100327.

• Zhang, F.F. et al. (2017) ‘Dietary Isoflavone Intake and All-Cause Mortality in Breast Cancer Survivors: the Breast Cancer Family Registry’, Cancer, 123(11), pp. 2070–2079. Available at: https://doi.org/10.1002/cncr.30615.

• Zhao, T.-T. et al. (2019) ‘Dietary isoflavones or isoflavone-rich food intake and breast cancer risk: A meta-analysis of prospective cohort studies’, Clinical Nutrition, 38(1), pp. 136–145. Available at: https://doi.org/10.1016/j.clnu.2017.12.006.